Author Archives: Modulight

Nanobody-targeted photodynamic therapy for the treatment of feline oral carcinoma: a step towards translation to the veterinary clinic

Published in: Nanophotonics Authors: Irati Beltrán Hernández, Guillaume C.M. Grinwis, Alessia Di Maggio, Paul M.P. van Bergen en Henegouwen, Wim E. Hennink, Erik Teske, Jan W. Hesselink, Sebastiaan A. van Nimwegen, Jan A. Mol, Sabrina Oliveira    Published in: Nanophotonics Authors: Irati Beltrán Hernández, Guillaume C.M. Grinwis, Alessia Di Maggio, Paul M.P. van Bergen en Henegouwen, Wim E. Hennink, Erik Teske, Jan W. Hesselink, Sebastiaan A. van Nimwegen, Jan A. Mol, Sabrina Oliveira   Nanobody-targeted PDT was shown in vitro to be suitable and efficient for oral carcinoma, which expresses EGFR. Modulight laser was used as an illumination source to activate PDT. Next aim is to treat cats with oral carcinoma before advancing to human clinic.   Read the article here

Rapid Depletion of Intratumoral Regulatory T cells Induces Synchronized CD8 T and NK Cell Activation and IFN-γ-dependent Tumor Vessel Regression

Published in: Cancer Research Authors: Yutaka Kurebayashi, Colleen P. Olkowski, Kelly C. Lane, Olga V. Vasalatiy, Biying C. Xu, Ryuhei Okada, Aki Furusawa, Peter L. Choyke, Hisataka Kobayashi, Noriko Sato    Published in: Cancer Research Authors: Yutaka Kurebayashi, Colleen P. Olkowski, Kelly C. Lane, Olga V. Vasalatiy, Biying C. Xu, Ryuhei Okada, Aki Furusawa, Peter L. Choyke, Hisataka Kobayashi, Noriko Sato   Tumor-infiltrating regulatory T cells (Tregs) were selectively depleted using anti-CD25 antibody fragment mediated NIR-PIT with ML7710 (50 J/cm2) in tumor-bearing mice. This induced transient IFN-γ expression in CD8 T and NK cells, which lead to efficient and rapid tumor vessel regression, intratumoral ischemia, and tumor necrosis/apoptosis and growth suppression. These results indicate the pivotal Continue reading →

Virus-like particle-drug conjugates induce protective, long-lasting adaptive anti-tumor immunity in the absence of specifically targeted tumor antigens

Published in: Cancer Immunology Research Authors: Rhonda C Kines, Cynthia D Thompson, Sean Spring, Zhenyu Li, Elisabet de los Pinos, Stephen Monks, John T Schiller       Related application note: Vision-sparing targeted phototherapy for uveal melanoma  Published in: Cancer Immunology Research Authors: Rhonda C Kines, Cynthia D Thompson, Sean Spring, Zhenyu Li, Elisabet de los Pinos, Stephen Monks, John T Schiller   This study examined the ability of a papillomavirus-like particle drug-conjugate (AU-011) to eradicate subcutaneous tumors after intravenous injection and to subsequently elicit long-term anti-tumor immunity in the TC-1 syngeneic murine tumor model. Also the combination of AU-011 with immune checkpoint inhibitor antibodies (anti-CTLA-4 or anti-PD-1) was studied and improved therapeutic efficacy. Modulight laser + MLAKIT was used only for Continue reading →

New Insights on Management of CSCR

Retinal Physician – May 1, 2021  Currently, most retina specialists use photodynamic therapy (PDT) with verteporfin (Visudyne; Bausch + Lomb). Photodynamic therapy devices include ML6710i (available for investigational use only in the United States) by Modulight and ML7710 (CE certified; available for investigational use only in the United States) by Modulight.Retinal Physician - May 1, 2021  Currently, most retina specialists use photodynamic therapy (PDT) with verteporfin (Visudyne; Bausch + Lomb). Photodynamic therapy devices include ML6710i (available for investigational use only in the United States) by Modulight and ML7710 (CE certified; available for investigational use only in the United States) by Modulight. Read article

Photochemical Internalization Enhanced Vaccination Is Safe, and Gives Promising Cellular Immune Responses to an HPV Peptide-Based Vaccine in a Phase I Clinical Study in Healthy Volunteers

Published in: Frontiers in Immunology Authors: Tone Otterhaug, Sylvia Janetzki, Marij J. P. Welters, Monika Håkerud, Anne Grete Nedberg, Victoria Tudor Edwards, Sanne Boekestijn, Nikki M. Loof, Pål Kristian Selbo, Hans Olivecrona, Sjoerd H. van der Burg, Anders Høgset    Published in: Frontiers in Immunology Authors: Tone Otterhaug, Sylvia Janetzki, Marij J. P. Welters, Monika Håkerud, Anne Grete Nedberg, Victoria Tudor Edwards, Sanne Boekestijn, Nikki M. Loof, Pål Kristian Selbo, Hans Olivecrona, Sjoerd H. van der Burg, Anders Høgset   Open-label phase 1 study to assess safety and local tolerance to PCI vaccination (fimaVACC). Peptide and protein-based vaccination coupled with PCI platform was safe in healthy volunteers (n=96) and significantly enhanced T-cell responses (over 10-fold compared to vaccination without PCI platform). The optimal and safe Continue reading →

Theranostic Prospects of Graphene Quantum Dots in Breast Cancer

Published in: ACS Biomaterials Science and Engineering Authors: Rahul S. Tade, Pravin O. Patil  Published in: ACS Biomaterials Science and Engineering Authors: Rahul S. Tade, Pravin O. Patil   Breast cancer (BC) is increasing as a significant cause of mortality among women. In this context, early diagnosis and treatment strategies for BC are being developed by researchers at the cellular level using advanced nanomaterials. However, immaculate etiquette is the prerequisite for their implementation in clinical practice. Considering the stolid nature of cancer, combining diagnosis and therapy (theranostics) using graphene quantum dots (GQDs) is a prime focus and challenge for Continue reading →

Near-infrared Absorbing Ru(II) Complexes Act as Immunoprotective Photodynamic Therapy (PDT) Agents Against Aggressive Melanoma

Published in: Chemical Science Authors: Liubov M. Lifshits, A. Roque III, Prathyusha Konda, Susan Monro, Houston D. Cole, David von Dohlen, Susy Kim, Gagan Deep, Randolph P. Thummel, Colin G. Cameron, Shashi Gujar, Sherri A. McFarland    Published in: Chemical Science Authors: Liubov M. Lifshits, A. Roque III, Prathyusha Konda, Susan Monro, Houston D. Cole, David von Dohlen, Susy Kim, Gagan Deep, Randolph P. Thummel, Colin G. Cameron, Shashi Gujar, Sherri A. McFarland   9 novel Ru-based coordination complexes with different ligands were systematically synthetized and explored with aim to long wavelengths (>700 nm – >1000 nm depending on the compound) and high singlet oxygen quentum yeild for melanoma PDT. Light dosimetry and phototoxicities were studied in vitro (ML8500) and in vivo. Continue reading →

Breaking the barrier: an osmium photosensitizer with unprecedented hypoxic phototoxicity for real world photodynamic therapy

Published in: Chemical Science Authors: John A. Roque III, Patrick C. Barrett, Houston D. Cole, Liubov M. Lifshits, Ge Shi, Susan Monro, David von Dohlen, Susy Kim, Nino Russo, Gagan Deep, Colin G. Cameron, Marta E. Alberto, Sherri A. McFarland    Published in: Chemical Science Authors: John A. Roque III, Patrick C. Barrett, Houston D. Cole, Liubov M. Lifshits, Ge Shi, Susan Monro, David von Dohlen, Susy Kim, Nino Russo, Gagan Deep, Colin G. Cameron, Marta E. Alberto, Sherri A. McFarland   ML8500 was used for specialized dosimetry studies in the development of the osmium-based PS using similar drug development strategy as for the analogous Ru(II) series that resulted in TLD1433 (first metal complex in clinical trials). The Os-compound approaches the ideal properties with multi-wavelength activation Continue reading →

Heat shock protein 90-targeted photodynamic therapy enables treatment of subcutaneous and visceral tumors

Published in: Communications Biology Authors: Kensuke Kaneko, Takuya Osada, Michael A. Morse, William R. Gwin, Joshua D. Ginzel, Joshua C. Snyder, Xiao-Yi Yang, Cong-Xiao Liu, Márcio A. Diniz, Khaldon Bodoor, Philip F. Hughes, Timothy AJ. Haystead, H. Kim Lyerly    Published in: Communications Biology Authors: Kensuke Kaneko, Takuya Osada, Michael A. Morse, William R. Gwin, Joshua D. Ginzel, Joshua C. Snyder, Xiao-Yi Yang, Cong-Xiao Liu, Márcio A. Diniz, Khaldon Bodoor, Philip F. Hughes, Timothy AJ. Haystead, H. Kim Lyerly   ML7710 was used for in vivo and ML8500 coupled to ML7710 for in vitro studies of HSP90-targeted verteporfin PDT for breast cancer. This strategy has both diagnostic and therapeutic potential across all breast cancer subtypes found up to few cm in depth, and may provide Continue reading →